13F reference period
Q3 2026
Security Snapshot
PALVELLA THERAPEUTICS, INC. - Common Stock (PVLA) Institutional Ownership
CUSIP: 697947109
13F Institutional Holders and Ownership History from Q4 2024 to Q3 2026
Institutions Reporting
106
Shares (Excl. Options)
5.58M
Full value: 5,581,772 · shares · 30 Sep 2026Price
$137.93
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- PVLA on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 5,581,772
- Total 13F value
- $770,087,113
- Portfolio coverage rank
- 0%
- Share change
- +1,014,887
- Value change
- +$138,075,363
- Number of holders
- 106
- Shares outstanding
- 14,307,169
- SEC-reported price per share
- $128.00
- Insider filing price
- $128.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 697947109.
- 106 institutions reported positions in Q3 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 195 to 106 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$2.15B
Full value: $2,146,394,669 · USD · 30 Jun 2026.$770.09M
Full value: $770,087,113 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 106 institutions filings for Q3 2026.
Security key
697947109
13F reference period
Q3 2026
13F holders
106
13D/G owners
10
CIK / CUSIP context first
Open Q3 2026 holders
PVLA full holder history
PALVELLA THERAPEUTICS, INC. SEC filings
PALVELLA THERAPEUTICS, INC. company facts
PALVELLA THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 697947109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
PVLA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kaupinen Wes | 15% | $38,555,729 | 1,644,869 | Kaupinen Wes | 13 Dec 2024 | |||
| JENNISON ASSOCIATES LLC | 7.7% | +14% | $151,951,742 | +$19,452,795 | 1,101,652 | +15% | Jennison Associates LLC | 30 Sep 2026 |
| PRUDENTIAL FINANCIAL INC | 6.7% | $140,535,475 | 962,374 | PRUDENTIAL FINANCIAL INC | 30 Jun 2026 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | -13% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| BlackRock, Inc. | 5.7% | $124,235,477 | 812,953 | BlackRock, Inc. | 30 Jun 2026 | |||
| First Light Asset Management, LLC | 5.3% | -31% | $112,314,156 | -$17,218,981 | 769,117 | -13% | First Light Asset Management, LLC | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. | 6% | +22% | $70,982,116 | +$16,164,419 | 706,360 | +29% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4.7% | -34% | $98,247,378 | -$30,114,307 | 672,789 | -23% | BVF PARTNERS L P/IL | 30 Jun 2026 |
| Samsara BioCapital, L.P. | 3.1% | -50% | $8,989,600 | -$8,989,600 | 339,743 | -50% | Samsara BioCapital, L.P. | 30 Jun 2025 |
| Dellora Investments LP | 1.3% | $3,306,892 | 141,079 | Dellora Investments LP | 13 Dec 2024 |
As of 30 Sep 2026,
106
institutional investors reported holding
shares of
PALVELLA THERAPEUTICS, INC. - Common Stock (PVLA).
This represents
39%
of the company’s total
outstanding shares.
5.58M
Full value: 5,581,772 · shares · 30 Sep 202614.31M
Full value: 14,307,169 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| STATE STREET CORP | 4.4% | 624,879 | -4.3% | 0% | $86,189,560 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 540,712 | +5.2% | 0% | $74,580,406 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2.8% | 396,045 | 0.18% | $54,626,487 | |
| FEDERATED HERMES, INC. | 2.3% | 332,422 | -23% | 0.06% | $45,850,966 |
| MARSHALL WACE, LLP | 2.3% | 329,799 | +11464% | 0.04% | $45,489,178 |
| Invesco Ltd. | 2.2% | 312,729 | +829% | 0% | $43,134,711 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 311,596 | +13% | 0% | $42,986,695 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.9% | 268,609 | +4.9% | 0.02% | $37,049,239 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.6% | 231,484 | 0% | 0.45% | $31,928,588 |
| EMERALD ADVISERS, LLC | 1.6% | 229,404 | -0.04% | 0.87% | $31,641,694 |
| Siren, L.L.C. | 1.5% | 207,485 | -19% | 0.68% | $28,618,406 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.4% | 195,070 | 0.09% | $26,906,005 | |
| MORGAN STANLEY | 1% | 145,065 | -20% | 0% | $20,008,901 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 0.99% | 142,111 | +9.4% | 0.8% | $19,601,370 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.95% | 135,246 | +4.9% | 0% | $18,654,481 |
| VANGUARD FIDUCIARY TRUST CO | 0.61% | 86,774 | +17% | 0% | $11,968,738 |
| Clio Asset Management LLC | 0.6% | 86,012 | -0.38% | 10% | $11,863,635 |
| NEXTBio Capital Management LP | 0.56% | 80,409 | -11% | 4.7% | $11,090,813 |
| AWM Investment Company, Inc. | 0.49% | 69,416 | 0% | 0.92% | $9,574,549 |
| NEUBERGER BERMAN GROUP LLC | 0.46% | 65,679 | -21% | 0.01% | $9,059,104 |
| Aberdeen Group plc | 0.44% | 63,347 | -47% | 0.01% | $8,737,452 |
| Clearbridge Investments, LLC | 0.41% | 59,240 | -0.17% | 0.01% | $8,170,973 |
| NAN FUNG TRINITY (HK) LTD | 0.37% | 52,630 | 0.7% | $7,259,256 | |
| ROYCE & ASSOCIATES LP | 0.35% | 50,509 | +25% | 0.06% | $6,966,706 |
| Lisanti Capital Growth, LLC | 0.29% | 41,990 | -2.3% | 1.6% | $5,791,681 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Headline period
Q3 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 5,581,772 | $770,087,113 | +$138,075,363 | $137.93 | 106 |
| 2026 Q2 | 14,091,179 | $2,146,394,669 | +$154,552,862 | $152.82 | 195 |
| 2026 Q1 | 13,189,583 | $1,638,162,825 | +$428,698,637 | $124.65 | 178 |
| 2025 Q4 | 9,759,838 | $1,021,544,191 | +$142,062,451 | $104.67 | 141 |
| 2025 Q3 | 8,525,488 | $534,466,075 | +$183,107,977 | $62.69 | 100 |
| 2025 Q2 | 5,909,706 | $133,205,244 | +$16,635,084 | $22.54 | 64 |
| 2025 Q1 | 5,123,397 | $143,404,590 | +$33,701,617 | $27.99 | 40 |
| 2024 Q4 | 4,033,052 | $48,417,227 | +$48,417,227 | $12.00 | 32 |